Source-grounded facts extracted from Dermata Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Dermata Therapeutics, Inc. reported financial results for quarter ended September 30, 2022.
“Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal period ended September 30, 2022.”
Christopher J. Nardo changed role as Senior Vice President, Chief Development Officer at Dermata Therapeutics, Inc..
“Christopher J. Nardo, Ph.D., the Company’s Senior Vice President of Development, was promoted to Senior Vice President, Chief Development Officer, effective July 1, 2022.”
Brittany Bradrick was appointed as Director at Dermata Therapeutics, Inc..
“the Board increased its size from seven to eight directors and appointed Brittany Bradrick as a Class II director to fill the newly created vacancy.”
Thomas Insley resigned as Chief Financial Officer at Dermata Therapeutics, Inc..
“On September 1, 2021, Thomas Insley resigned as Chief Financial Officer of the Company.”
Kyri Van Hoose was appointed as Senior Vice President, Chief Financial Officer at Dermata Therapeutics, Inc..
“appointed Kyri Van Hoose as Senior Vice President, Chief Financial Officer, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.